Neoadjuvant immunotherapy for resectable stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can improve outcomes for patients with a certain type of stomach or esophageal cancer that can be surgically removed. It aims to see if this approach shrinks tumors and helps prevent recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer called adenocarcinoma that starts near the junction of the esophagus and stomach and is considered operable (can be removed with surgery).
- Your cancer has not spread to distant organs (no metastasis) and is at a stage that allows for complete surgical removal.
- You are 18 years or older and in generally good health (able to do daily activities without significant limitation).
- You have not received any prior treatment for this cancer, such as chemotherapy, radiation, or surgery.
- You are willing to follow the study schedule and do not have any medical conditions that would make surgery unsafe.
- If you are of childbearing potential, you must agree to use effective contraception during the study and for six months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This Phase 3 trial studies whether adding an immune medicine called PD-1 (given as an “inhibitor”) to standard chemotherapy and chemoradiation after stomach/GEJ cancer surgery can lower the risk of cancer coming back. You may qualify if you’ve had surgery removing the tumor and lymph nodes showed higher-risk disease.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (a treatment that helps your immune system fight cancer) with radiation therapy for a certain type of stomach or gastroesophageal junction cancer that has a special genetic marker. The goal is to see if this combination is safe and effective.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.